Most antiviral drugs are built around a fundamental vulnerability: they target the virus directly, which means a single mutation can render them useless. A blood-thinning medication already in medicine cabinets may sidestep that problem entirely by enlisting the immune system itself as the weapon — a strategy that viruses cannot easily evolve around.
Betrixaban, an oral Factor Xa inhibitor approved for venous thromboembolism prevention, was found to trigger antiviral immunity through two molecularly distinct channels at once. First, the compound directly binds and activates cGAS — the cytosolic DNA sensor — stimulating production of cGAMP and launching the STING-interferon axis. This makes betrixaban the first small molecule documented to directly engage cGAS in this way. Simultaneously, betrixaban inhibits histone deacetylases (HDACs), loosening chromatin compaction around normally silenced endogenous retroviruses (ERVs). The derepressed ERVs produce immunostimulatory double-stranded RNA detected by the RIG-I/MDA5 pathway. These parallel signals converge on strong type I interferon induction, with demonstrated protection against both RNA and DNA viruses in cell culture and animal models.
The dual-pathway mechanism is conceptually striking and scientifically timely. The cGAS-STING axis has attracted intense therapeutic interest across oncology, autoimmunity, and infectious disease, yet finding orally bioavailable small molecules that directly activate — rather than merely modulate — cGAS has been elusive. That a clinically approved oral drug achieves this, while also independently activating ERV-derived dsRNA sensing, represents a genuinely unexpected convergence. The HDAC-ERV connection has been explored in cancer immunotherapy but rarely framed as a standalone antiviral mechanism. Key limitations are significant: the in vivo data are early-stage, the therapeutic window relative to anticoagulant and immune-activation side effects is uncharacterized in humans, and translating robust interferon responses into safe clinical practice remains a historically difficult challenge. Still, this study is more than incremental — it reframes a known drug's pharmacology and provides a testable host-directed antiviral framework worth rigorous follow-up.